Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Innovation Cancer

QUOTED. Jan. 8, 2019. Johnathan Lancaster.

  • News

Executive Summary

The UK's National Institute for Health and Care Excellence (NICE) added Myriad Genetics' EndoPredict test to its recommendations for breast-cancer treatment as new data show the long-term prognostic value of the EndoPredict test in guiding therapy for many of these patients. See what the firm's chief medical officer has to say about it here.

"Hopefully it will be a game-changing offering to the clinical market place and I'm highly optimistic that this is going to be incredibly well received and will be a source of improvements in outcomes for patients." – Johnathan Lancaster, chief medical officer, Myriad Genetics

Click here for a free trial of Medtech Insight.

 

 

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Innovation Cancer
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT124460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By